Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Circulating Tumour Cells and prostate cancer outcome
In Canada, 25,500 men will be diagnosed with prostate cancer in 2011, and 4,100 will
die of the disease. New approaches are required to predict clinical outcome and personalized
management of patients. Drs. Mai and Cayre will combine their two newly developed
technologies and work towards obtaining a new solid biomarker that enables the assessment
of a patient’s clinical outcome from the start. With the use of special filters, circulating tumour
cells (CTC) will be isolated from prostate cancer patients’ blood. These cells are
characterized using three-dimensional (3D) imaging of telomeres (the ends of chromosomes)
in the cells’ nuclei. This will be the first time these new technologies are combined to
investigate the link between CTCs, their 3D telomeric profiles and clinical outcome of prostate
cancer. A much better understanding and personalized management of prostate cancer,
which is a major goal of Cancercare Manitoba will be achieved by this project.
Faculty Supervisor:
Sabine Mai
Student:
Partner:
Cancer Care (Manitoba);Carl Zeiss Canada
Discipline:
Life Sciences
Sector:
Manufacturing
University:
University of Manitoba
Program:
Accelerate
Current openings
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find Projects
International
Load More
International
Load More
